Nintedanib for the Prevention of Radiation Pneumonia in Unresectable NSCLC

RecruitingOBSERVATIONAL
Enrollment

40

Participants

Timeline

Start Date

August 24, 2024

Primary Completion Date

May 31, 2026

Study Completion Date

June 30, 2026

Conditions
NSCLCNintedanibRadiation Pneumonitis
Interventions
DRUG

Nintedanib

For patients with unresectable NSCLC, nidanib is administered during sequential radiotherapy

Trial Locations (7)

Unknown

RECRUITING

Jincheng General Hospital, Jincheng

RECRUITING

Jinzhong third people's hospital, Jinzhong

RECRUITING

Frist Hospital of Shanxi Medical University, Taiyuan

RECRUITING

Second Hospital of Shanxi Medical University, Taiyuan

RECRUITING

Shanxi Bethune Hospital, Taiyuan

RECRUITING

Shanxi Hospital of Traditional Chinese Medicine, Taiyuan

RECRUITING

TISCO General Hospital, Taiyuan

All Listed Sponsors
lead

Second Hospital of Shanxi Medical University

OTHER